Robert Martin - Cymabay Therapeu Senior Development
| CBAYDelisted Stock | USD 11.83 0.27 2.34% |
Executive
Robert Martin is Senior Development of Cymabay Therapeu
| Age | 62 |
| Phone | 510 293 8800 |
| Web | https://www.cymabay.com |
Robert Martin Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Martin against Cymabay Therapeu stock is an integral part of due diligence when investing in Cymabay Therapeu. Robert Martin insider activity provides valuable insight into whether Cymabay Therapeu is net buyers or sellers over its current business cycle. Note, Cymabay Therapeu insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cymabay Therapeu'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Martin over three months ago Disposition of 5932 shares by Robert Martin of Thor Industries at 107.12 subject to Rule 16b-3 | ||
Robert Martin over three months ago Disposition of 7176 shares by Robert Martin of Thor Industries at 75.65 subject to Rule 16b-3 | ||
Robert Martin over six months ago Disposition of 5959 shares by Robert Martin of Thor Industries at 72.4 subject to Rule 16b-3 |
Cymabay Therapeu Management Efficiency
The company has return on total asset (ROA) of (0.2205) % which means that it has lost $0.2205 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6417) %, meaning that it created substantial loss on money invested by shareholders. Cymabay Therapeu's management efficiency ratios could be used to measure how well Cymabay Therapeu manages its routine affairs as well as how well it operates its assets and liabilities.Cymabay Therapeu currently holds 114.49 M in liabilities with Debt to Equity (D/E) ratio of 1.45, which is about average as compared to similar companies. Cymabay Therapeu has a current ratio of 11.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cymabay Therapeu's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Soojin Kim | Inozyme Pharma | N/A | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| John Schembri | Akero Therapeutics | 63 | |
| Ravi Upasani | Biomea Fusion | N/A | |
| Paul Shin | 89bio Inc | N/A | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Myesha Lacy | Arcellx | N/A | |
| Mike JD | Pliant Therapeutics | 52 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Suba Krishnan | Mereo BioPharma Group | 60 | |
| JD Esq | Terns Pharmaceuticals | 56 | |
| Melissa Manno | Kiniksa Pharmaceuticals | N/A | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Yingli Ma | Structure Therapeutics American | 51 | |
| Eric MD | Pliant Therapeutics | 61 | |
| Matt Cravets | Gossamer Bio | N/A | |
| Thorsten Kirschberg | Biomea Fusion | 55 | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Jonathan JD | Stoke Therapeutics | 35 | |
Management Performance
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 |
Cymabay Therapeu Leadership Team
Elected by the shareholders, the Cymabay Therapeu's board of directors comprises two types of representatives: Cymabay Therapeu inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cymabay. The board's role is to monitor Cymabay Therapeu's management team and ensure that shareholders' interests are well served. Cymabay Therapeu's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cymabay Therapeu's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, Chief Officer | ||
| Paul Quinlan, General Counsel, Corporate Secretary | ||
| Patrick OMara, Senior Development | ||
| Robert Martin, Senior Development | ||
| Sujal Shah, CFO and Secretary | ||
| Klara DickinsonEason, Chief Officer | ||
| MBA MD, Chief Officer | ||
| Ken Boehm, Senior Resources | ||
| Harish CFA, Chief Officer | ||
| Ben Kozub, Head Commercial | ||
| Charles McWherter, Chief Scientific Officer and Sr. VP | ||
| Becki Filice, Senior Leadership | ||
| Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer |
Cymabay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cymabay Therapeu a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (745.58) % | |||
| Current Valuation | 3.45 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 0.51 % | |||
| Shares Owned By Institutions | 99.49 % | |||
| Number Of Shares Shorted | 5.85 M | |||
| Price To Earning | (8.62) X | |||
| Price To Book | 12.76 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |